EP1476018A4 - Immunstimulierende zusammensetzungen, die aminoalkylglucosamidinphosphate und saponine enthalten - Google Patents

Immunstimulierende zusammensetzungen, die aminoalkylglucosamidinphosphate und saponine enthalten

Info

Publication number
EP1476018A4
EP1476018A4 EP02706143A EP02706143A EP1476018A4 EP 1476018 A4 EP1476018 A4 EP 1476018A4 EP 02706143 A EP02706143 A EP 02706143A EP 02706143 A EP02706143 A EP 02706143A EP 1476018 A4 EP1476018 A4 EP 1476018A4
Authority
EP
European Patent Office
Prior art keywords
saponins
aminoalkyl glucosaminide
glucosaminide phosphates
immunostimulant compositions
immunostimulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02706143A
Other languages
English (en)
French (fr)
Other versions
EP1476018A1 (de
Inventor
Sally Mossman
Lawrence Evans
Jory R Baldridge
Jay T Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Agenus Inc
Original Assignee
Corixa Corp
Antigenics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Antigenics LLC filed Critical Corixa Corp
Publication of EP1476018A1 publication Critical patent/EP1476018A1/de
Publication of EP1476018A4 publication Critical patent/EP1476018A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
EP02706143A 2002-02-04 2002-02-04 Immunstimulierende zusammensetzungen, die aminoalkylglucosamidinphosphate und saponine enthalten Withdrawn EP1476018A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/003313 WO2003069997A1 (en) 2002-02-04 2002-02-04 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins

Publications (2)

Publication Number Publication Date
EP1476018A1 EP1476018A1 (de) 2004-11-17
EP1476018A4 true EP1476018A4 (de) 2005-09-21

Family

ID=27752544

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02706143A Withdrawn EP1476018A4 (de) 2002-02-04 2002-02-04 Immunstimulierende zusammensetzungen, die aminoalkylglucosamidinphosphate und saponine enthalten

Country Status (5)

Country Link
EP (1) EP1476018A4 (de)
JP (1) JP2005525344A (de)
AU (1) AU2002240250A1 (de)
CA (1) CA2477191A1 (de)
WO (1) WO2003069997A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
CA2708718A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
CN110833555B (zh) * 2018-08-15 2023-03-24 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗溃疡性结肠炎的用途
JP2022516043A (ja) * 2018-12-21 2022-02-24 サプリーム テクノロジーズ，ベー．フェー． 生物活性な分子のクラスター
CN110317794A (zh) * 2019-06-12 2019-10-11 吉林特研生物技术有限责任公司 一种重组杆状病毒、貉细小病毒重组亚单位疫苗及其制备方法
KR20230043113A (ko) * 2020-06-24 2023-03-30 사프렘 테크놀로지스 비.브이. 의약용 사포닌 유도체
WO2024065107A1 (en) * 2022-09-26 2024-04-04 Powin Biomedical Co., Ltd. Novel compositions comprising terpenoid and macromolecule, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053363A1 (en) * 2000-03-17 2001-12-20 Johnson David A. Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors
WO2002003961A1 (en) * 2000-07-07 2002-01-17 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500779A (en) * 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053363A1 (en) * 2000-03-17 2001-12-20 Johnson David A. Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors
WO2002003961A1 (en) * 2000-07-07 2002-01-17 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03069997A1 *

Also Published As

Publication number Publication date
JP2005525344A (ja) 2005-08-25
CA2477191A1 (en) 2003-08-28
WO2003069997A1 (en) 2003-08-28
EP1476018A1 (de) 2004-11-17
AU2002240250A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
AU2002357119A8 (en) Mitocidal compositions and methods
HK1153229A1 (en) Minicell compositions and methods
IL163549A0 (en) Topiramate salts and compositions comprising and methods of making and using the same
EP1365784A4 (de) Verfahren und vorrichtungen für die gewebereparatur
IL169540A0 (en) Certain aminoalkyl glucosaminide phosphate compounds and their use
GB9924351D0 (en) Immunomodulation methods and compositions
HK1095743A1 (en) Ccn1 compositions and methods ccn1
AU2002353383A8 (en) Cleaning and desinfecting herbal compositions and their preparation
AU2003275268A8 (en) Hemostatic compositions and methods
EP1455841A4 (de) Osteopontin-verwandte zusammensetzungen und verfahren
GB2380672B (en) Herbal formulation
AU2003213120A8 (en) Human rnase iii and compositions and uses thereof
EP1476018A4 (de) Immunstimulierende zusammensetzungen, die aminoalkylglucosamidinphosphate und saponine enthalten
GB2378384B (en) Herbal formulation
IL158764A0 (en) Methods and compositions for making emamectin
GB2378385B (en) Herbal formulation
AU2002353078A8 (en) Tissue graft compositions and methods for producing same
AU2002366809A8 (en) Syn3 compositions and methods
AU2001261317A1 (en) Immunostimulant compositions and associated methods
AU2003263962A8 (en) Tissue compositions and methods for producing same
AU2002359869A8 (en) Pak5-related compositions and methods
EP1286372A4 (de) Elektrischer flutungsschalter und verfahren zu seiner herstellung
GB0107033D0 (en) Method and composition
AU2003218460A8 (en) Compositions and methods for immunomodulation
SI1418942T1 (sl) Sestavki, ki vsebujejo poksvirus, in postopek za njihovo pripravo

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040827

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: EVANS, JAY, T.

Inventor name: BALDRIDGE, JORY, R.

Inventor name: EVANS, LAWRENCE

Inventor name: MOSSMAN, SALLY

A4 Supplementary search report drawn up and despatched

Effective date: 20050809

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061010